Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmaceutical Research

• Publication date

  2016-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11095-015-1785-0PMID 26337772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013cited by this paper
• Pharmacokinetic alteration of (99m)Tc-MAG3 using serum protein binding displacement method.

  2013cited by this paper
• Removal of Protein-Bound Uraemic Toxins by Haemodialysis

  2013cited by this paper
• Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans

  2013cited by this paper
• Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

  2012cited by this paper
• Interaction between Two Sulfate-Conjugated Uremic Toxins, p-Cresyl Sulfate and Indoxyl Sulfate, during Binding with Human Serum Albumin

  2012cited by this paper
• Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure

  2011cited by this paper
• Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure

  2011cited by this paper
• Plasma protein carbonylation in chronic uremia.

  2011cited by this paper
• The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

  2008cited by this paper
• Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.

  2007cited by this paper
• Inconsistency of reported uremic toxin concentrations.

  2007cited by this paper
• Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

  2006cited by this paper
• Increased plasma protein homocysteinylation in hemodialysis patients.

  2006cited by this paper
• Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics

  2005cited by this paper
• Review on uremic toxins: classification, concentration, and interindividual variability.

  2003cited by this paper
• Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• Interaction Mechanism Between Indoxyl Sulfate, a Typical Uremic Toxin Bound to Site II, and Ligands Bound to Site I of Human Serum Albumin

  2001cited by this paper
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001cited by this paper
• Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan

  2001cited by this paper
• Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.

  2001cited by this paper
• Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

  2000cited by this paper
• The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.

  2000cited by this paper
• Pharmacokinetics of repaglinide in subjects with renal impairment

  2000cited by this paper
• In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood

  2000cited by this paper
• Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.

  1998cited by this paper
• Irinotecan (CPT-11) metabolism and disposition in cancer patients.

  1998cited by this paper
• Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.

  1997cited by this paper
• Mode of Interaction of Loop Diuretics with Human Serum Albumin and Characterization of Binding Site

  1996cited by this paper
• Characterization of binding site of uremic toxins on human serum albumin.

  1995cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper

• Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

  2025cites this paper
• Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin‐I as an Endogenous Biomarker

  2025cites this paper
• Relationship of plasma 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease

  2024cites this paper
• Induction of open-form bile canaliculus formation by hepatocytes for evaluation of biliary drug excretion

  2023cites this paper
• Pharmacokinetic profile of irinotecan in patients with chronic kidney disease: Two cases and literature review

  2023cites this paper
• Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction

  2023influential citation
• Special Section on Mechanism-Based Predictive Methods in Drug Discovery and Development — Minireview Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction

  2023cites this paper
• Bile Acid–Drug Interaction via Organic Anion-Transporting Polypeptide 4C1 Is a Potential Mechanism of Altered Pharmacokinetics of Renally Excreted Drugs

  2022cites this paper
• The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction

  2022cites this paper
• Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients

  2022influential citation
• Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer.

  2021cites this paper
• Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure

  2021cites this paper
• Factors Influencing Plasma Coproporphyrin‐I Concentration as Biomarker of OATP1B Activity in Patients With Rheumatoid Arthritis

  2021cites this paper
• Assessment of drug-drug interaction and optimization in capecitabine and irinotecan combination regimen using a physiologically based pharmacokinetic model.

  2021cites this paper
• Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B

  2021cites this paper
• 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients.

  2020cites this paper
• Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system.

  2020cites this paper
• Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview

  2020cites this paper
• Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability

  2020cites this paper
• Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population

  2020cites this paper
• Pharmakokinetik von Tumortherapeutika bei normaler und eingeschränkter Nierenfunktion

  2020cites this paper
• Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure

  2019cites this paper
• Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

  2019cites this paper
• Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

  2018cites this paper
• Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease

  2018cites this paper
• Relationship Between Renal Dysfunction and Oral Mucositis in Patients Undergoing Concurrent Chemoradiotherapy for Pharyngeal Cancer: A Retrospective Cohort Study

  2018cites this paper
• Food–drug interactions involving multiple mechanisms: A case study with effect of Capsaicin on the pharmacokinetics of Irinotecan and its main metabolites in rat

  2018cites this paper
• Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection.

  2018cites this paper
• Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model

  2017cites this paper
• Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs

  2017cites this paper
• Human microbiome signatures of differential colorectal cancer drug metabolism

  2017cites this paper
• Guidelines for treatment of renal injury during cancer chemotherapy 2016

  2017cites this paper
• Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

  2017cites this paper
• Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects

  2017cites this paper
• Pharmacokinetics and safety of letermovir, a novel anti‐human cytomegalovirus drug, in patients with renal impairment

  2017cites this paper